Literature DB >> 9463585

Thymic epithelial tumor progression in an SV40T transgenic mouse model. Cortical thymoma-thymic carcinoma sequence.

S S Lee1, W Y Park, J G Chi, J W Seo, J I Kim, C W Kim, S H Park, S K Khang, K J Cho, J S Seo, J J Jang.   

Abstract

There have been several reports that thymoma in human is a progressive disease, and that thymoma and thymic carcinoma form a continuum. We established a stable line of SV40T transgenic mice, which consistently produced thymic epithelial tumours progressing to thymic carcinoma within a predictable time span. Using this animal model and a morphological approach, thymic epithelial tumour progression was studied with reference to sequential changes at different time points in animals aged from 3 to 32 weeks. At all ages, SV40T was expressed in the nuclei of thymic epithelial cells; in these transgenic mice we observed the entire spectrum from cortical type thymoma to thymic carcinoma. Thymic size tended to increase with ageing in SV40T TG mice. While younger mice had predominantly cortical (organoid) or cortical thymoma, older mice had well-differentiated thymic carcinoma (WDTC) or poorly differentiated thymic carcinoma. When SV40T TG mice (248 line) reached a certain age, carcinoma of the thymus was present in all of them. Cortical-type thymoma became malignant within a predictable time span, suggesting a cortical thymoma-carcinoma sequence. When the mice were 9 weeks of age, the thymuses formed gross masses compatible with cortical thymoma. At 14 weeks of age, WDTC appeared against the background of cortical thymoma. Poorly differentiated thymic carcinoma was found after 15 weeks and affected all animals over 23 weeks of age. Most thymic carcinomas coexisted in varying proportions with cortical-type thymoma. Medullary thymomas did not develop in the mice, and no transition from medullary-type thymomas to thymic carcinomas was observed. In this SV40T transgenic mouse model, thymic carcinoma is clearly preceded by cortical-type thymoma. These transgenic mice may provide an interesting model for the progression from cortical thymoma to WDTC and/or high-grade carcinoma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9463585     DOI: 10.1007/s004280050131

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  5 in total

1.  Neoplastic transformation and angiogenesis in the thymus of transgenic mice expressing SV40 T and t antigen under an L-pyruvate kinase promoter (SV12 mice).

Authors:  Bernadette Nabarra; Christiane Pontoux; Cecile Godard; Mary Osborne-Pellegrin; Sophie Ezine
Journal:  Int J Exp Pathol       Date:  2005-12       Impact factor: 1.925

2.  Comparative Incidences and Biological Outcomes for Thymoma in Various Rat Strains in National Toxicology Program Studies.

Authors:  Rebecca R Moore; Hiroaki Nagai; Rodney A Miller; Jerry F Hardisty; Neil Allison; Keith R Shockley; David E Malarkey
Journal:  Toxicol Pathol       Date:  2019-08-08       Impact factor: 1.902

3.  Thymoma originating from the cervical component of the thymus in a degu.

Authors:  Naka Okumura; Hirotaka Kondo; Shinichi Suzuki; Hisashi Shibuya
Journal:  J Vet Diagn Invest       Date:  2021-09-13       Impact factor: 1.569

4.  A novel animal model of thymic tumour: development of epithelial thymoma in transgenic rats carrying human T lymphocyte virus type I pX gene.

Authors:  Kazunori Kikuchi; Hitoshi Ikeda; Takahiro Tsuchikawa; Takahiro Tsuji; Satoshi Tanaka; Kazunori Fugo; Toshiaki Sugaya; Yuetsu Tanaka; Masatoshi Tateno; Naoki Maruyama; Takashi Yoshiki
Journal:  Int J Exp Pathol       Date:  2002-10       Impact factor: 1.925

5.  The treatment and survival of patients with postoperative recurrent thymic carcinoma and neuroendocrine carcinoma: a multicenter retrospective study.

Authors:  Ryo Miyata; Masatsugu Hamaji; Mitsugu Omasa; So Miyahara; Akihiro Aoyama; Yutaka Takahashi; Ryota Sumitomo; Cheng-Long Huang; Kyoko Hijiya; Tatsuo Nakagawa; Yuhei Yokoyama; Kenzo Kawakami; Makoto Sonobe; Masaki Ikeda; Takuji Fujinaga; Michiharu Suga; Shinya Hirota; Fumitsugu Kojima; Toru Bando; Mamoru Takahashi; Yasuji Terada; Tsuyoshi Shoji; Hiromichi Katakura; Yusuke Muranishi; Ryo Miyahara; Hiroshi Date
Journal:  Surg Today       Date:  2020-08-10       Impact factor: 2.549

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.